At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 413 enrolled
Drug / intervention
Azilsartan medoxomil +2 moredrug
Likely dose
Azilsartan medoxomil 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Azilsartan medoxomil and Placebo for Hypertension. Completed, enrolled 413 participants across 64 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedJan 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedJan 11, 2008
Enrollment StartOct 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.5 years ago
Interventions
Azilsartan medoxomildrug
Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
Azilsartan medoxomildrug
Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
Placebodrug
Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.